Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter. However, management reduced 2025 growth guidance for sales (8% ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...